Business Wire

Boomi Appoints New Leaders To Support Rapid Customer Growth After Successful Spin Off As A Newly Independent Company

13.6.2022 16:20:00 EEST | Business Wire | Press release

Share

Boomi™, the intelligent connectivity and automation leader, today announced the appointment of Madeline Ling as chief financial officer (CFO), Marcy Campbell as chief revenue officer (CRO), and Fran Wilson as chief marketing officer (CMO), effective immediately. Additionally, Emmy award-winning news journalist Christa Delcamp joins Boomi to support public relations and media strategy, and James Dyson joins the company to lead Global Diversity, Equity, and Inclusion Talent Acquisition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005227/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Attracts Industry Leaders For Next Stage Of Growth (Graphic: Business Wire)

“Boomi's recent launch as a standalone company – coupled with our high growth and cutting-edge, cloud-based technology – provides the opportunity to build our leadership team as part of a much larger expansion, with several hundred new hires coming onboard this year,” said David Meredith, CEO at Boomi. “Our industry-leading platform and award-winning culture enabled us to recruit top, globally-minded talent, with a demonstrated track-record of achievement, and a passion to accelerate our mission to make the world a better place by connecting everyone to everything, anywhere.”

The new leadership appointments come after Boomi's recent independence backed by premier private equity firms, Francisco Partners and TPG, in a $4 billion transaction. As a global software as a service (SaaS) category leader with more than 20,000 customers – Boomi touts a growing user community of over 100,000 members, a worldwide network of more than 800 partners, and one of the largest arrays of global system integrators (GSI) in the iPaaS space, which includes Accenture, Deloitte, SAP, and Snowflake, as well as the three largest cloud providers, Amazon Web Services, Google, and Microsoft, among others.

Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for enterprise platform as a service (EiPaaS)1 for eight consecutive years. The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces. As the company continues to scale rapidly to meet global, enterprise demand for digital connectivity, integration, and automation, Boomi plans to hire several hundred new team members this year to accelerate all functions of the business.

BOOMI ATTRACTS WORLD-CLASS TALENT:

Madeline Ling, CFO
Ling holds a MBA from Stanford Graduate School of Business, and brings nearly 25 years of experience leading equity-backed, global enterprise organizations through strategic and international growth. She has held multiple CFO roles throughout her career, including international assignments overseas. Ling most recently served as corporate CFO for a Hellman and Friedman (H&F) PE-backed portfolio company, and held previous roles at VMware, The Boston Consulting Group, and Intel.

Marcy Campbell, CRO
Campbell brings to Boomi over 30 years of experience leading large-scale, go-to-market organizations for global companies ranging from Fortune 500 to venture-backed technology firms. She most recently served as senior vice president at PayPal where she led global sales, professional services, and operations. At Boomi, Campbell will spearhead the company’s revenue-generating strategies with a focus on driving fast growth, while continuing to deliver customer value.

Fran Wilson, CMO
With more than 20 years of successful experience in SaaS and B2B enterprise software organizations, Wilson provided marketing leadership through Red Hat’s initial public offering (IPO), and during its rapid revenue growth from $400 million to more than $4 billion, culminating in its sale to IBM for $34 billion.

Christa Delcamp, Public Relations and Media Strategy
Delcamp brings over two decades of experience in public relations, journalism, content creation, and communications, across a variety of platforms, including digital/social, NBC and CBS-owned and operated stations, radio/podcasting, and print. An Emmy award-winning news journalist, Delcamp’s extensive expertise in telling impactful stories will help Boomi increase market awareness of its industry-leading platform and important mission to connect the world.

James Dyson, Global Diversity, Equity, and Inclusion (DE&I) Talent Acquisition
Dyson brings over 20 years of experience leading and managing talent acquisition at global companies, including Accenture. In his role, Dyson will leverage his deep expertise and extensive international network to support Boomi’s rapid growth and continue to build the company’s award-winning culture.

Additional Resources

Gartner Disclaimer:

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.

About Boomi

Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.

© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

________________________
1 Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye